Primary |
Epilepsy |
20.1% |
Prophylaxis |
17.4% |
Status Epilepticus |
14.6% |
Convulsion |
13.5% |
Convulsion Prophylaxis |
5.7% |
Product Used For Unknown Indication |
5.2% |
Anaesthesia |
3.1% |
Sedation |
2.9% |
Ill-defined Disorder |
2.6% |
Fluid Replacement |
2.1% |
Hypertension |
2.1% |
Postoperative Care |
1.6% |
Cerebral Infarction |
1.3% |
Constipation |
1.3% |
Encephalopathy |
1.3% |
Prophylaxis Against Gastrointestinal Ulcer |
1.3% |
Cardiac Failure |
1.0% |
Escherichia Infection |
1.0% |
Oedema |
1.0% |
Brain Oedema |
0.8% |
|
Thrombocytopenia |
12.5% |
Toxic Epidermal Necrolysis |
12.5% |
Respiratory Arrest |
8.8% |
Rhabdomyolysis |
8.8% |
Toxicity To Various Agents |
6.3% |
Rash |
5.0% |
Vomiting |
5.0% |
Blood Creatine Phosphokinase Increased |
3.8% |
Hypotension |
3.8% |
Medication Error |
3.8% |
Oedema Peripheral |
3.8% |
Overdose |
3.8% |
Respiratory Depression |
3.8% |
Supraventricular Extrasystoles |
3.8% |
Blood Lactate Dehydrogenase Increased |
2.5% |
Brain Neoplasm |
2.5% |
Cardiotoxicity |
2.5% |
Death |
2.5% |
Dyspnoea |
2.5% |
Encephalitis |
2.5% |
|
Secondary |
Epilepsy |
15.1% |
Fluid Replacement |
10.9% |
Status Epilepticus |
10.7% |
Convulsion |
9.6% |
Prophylaxis |
8.7% |
Oedema |
7.0% |
Prophylaxis Against Gastrointestinal Ulcer |
3.8% |
Analgesic Therapy |
3.5% |
Brain Oedema |
3.5% |
Constipation |
3.5% |
Electrolyte Substitution Therapy |
3.5% |
Hyperglycaemia |
3.5% |
Nausea |
3.5% |
Hyperammonaemia |
2.9% |
Sedation |
2.7% |
Drug Use For Unknown Indication |
2.1% |
Gastrointestinal Haemorrhage |
1.4% |
Pneumonia Aspiration |
1.4% |
Anaesthesia |
1.3% |
Convulsion Prophylaxis |
1.3% |
|
Brain Neoplasm |
36.5% |
Toxicity To Various Agents |
15.1% |
Toxic Epidermal Necrolysis |
4.8% |
Vomiting |
4.8% |
Intestinal Ischaemia |
4.0% |
Rhabdomyolysis |
3.2% |
Status Epilepticus |
3.2% |
Hepatic Function Abnormal |
2.4% |
Medication Error |
2.4% |
Muscle Spasms |
2.4% |
Pneumonia |
2.4% |
Post Procedural Haemorrhage |
2.4% |
Pyrexia |
2.4% |
Renal Impairment |
2.4% |
Thrombocytopenia |
2.4% |
Urinary Bladder Haemorrhage |
2.4% |
White Blood Cell Count Decreased |
2.4% |
Cerebral Infarction |
1.6% |
Cytolytic Hepatitis |
1.6% |
Drug Ineffective |
1.6% |
|
Concomitant |
Product Used For Unknown Indication |
38.1% |
Epilepsy |
9.1% |
Convulsion |
5.1% |
Status Epilepticus |
5.1% |
Breast Cancer Metastatic |
4.6% |
Depression |
4.6% |
Drug Use For Unknown Indication |
4.1% |
Acute Lymphocytic Leukaemia |
3.0% |
Cardio-respiratory Arrest |
3.0% |
Liver Transplant |
3.0% |
Acute Graft Versus Host Disease |
2.5% |
Borderline Personality Disorder |
2.5% |
Grand Mal Convulsion |
2.5% |
Pain |
2.5% |
Anxiety |
2.0% |
Bone Pain |
2.0% |
Anaemia |
1.5% |
Bone Marrow Conditioning Regimen |
1.5% |
Nausea |
1.5% |
Premedication |
1.5% |
|
Status Epilepticus |
18.8% |
Urinary Tract Infection |
12.5% |
Drug Ineffective |
6.3% |
Hepatitis Toxic |
6.3% |
Sepsis |
6.3% |
Thrombotic Microangiopathy |
6.3% |
Anaemia Haemolytic Autoimmune |
3.1% |
Aplasia |
3.1% |
Brain Injury |
3.1% |
Candidiasis |
3.1% |
Cerebrovascular Accident |
3.1% |
Drug Interaction |
3.1% |
Fracture |
3.1% |
Haemorrhage Intracranial |
3.1% |
Hepatic Failure |
3.1% |
Infusion Related Reaction |
3.1% |
Metabolic Acidosis |
3.1% |
Multi-organ Failure |
3.1% |
Nausea |
3.1% |
Neurological Symptom |
3.1% |
|
Interacting |
|
|